Full Report

Know the Business

Hims & Hers is a direct-to-consumer subscription pharmacy wrapped in a thin telehealth layer — customers come for generic, lifestyle-sensitive prescriptions (hair, sex, weight, skin, mood), and the real business is the $800M-a-year marketing machine that converts them into recurring refill-shippers at a 6–7 month payback. The bull case is that personalized, vertically-integrated fulfillment is the moat and GLP-1 is just kindling; the bear case is that this is a paid-acquisition retailer masquerading as healthcare, whose best-margin line (compounded semaglutide) is living on regulatory time. The market is almost certainly overweighting GLP-1 headlines and underweighting the fact that the majority of FY25 revenue already comes from non-GLP-1 offerings compounding at high double-digit rates.

How This Business Actually Works

The engine is a three-step loop: buy a customer with advertising, route them through an algorithmic clinical workflow, and ship them compounded or generic product on a recurring cadence. Every improvement to that loop — a cheaper ad channel, a higher-priced personalized SKU, a longer retention tail — shows up quickly in unit economics.

Three features determine whether this loop actually makes money:

1. Payback under one year, not cohort LTV. Management runs marketing to a 6–7 month gross-profit payback — the weakest discipline on the P&L is actually the most disciplined. Marketing dropped from 51% of revenue in FY23 to 39% in FY25 despite a Super Bowl ad; that is the leverage, not the 74% gross margin.
2. Personalization is pricing power, not clinical breakthrough. "Personalized" = a multi-drug or multi-dose compound that is (a) not a generic equivalent, (b) not reimbursable, and (c) only available on the platform. In FY25 personalized crossed 70% of US revenue, which is why ARPU jumped 28% to $83 despite only 13% subscriber growth.
3. Vertical fulfillment converts scale into margin, slowly. Four pharmacies, a 503B outsourcing facility, a peptide facility, and a lab facility — 1M sq ft and $300M of capex over three years. The quid pro quo is the FY25 gross-margin dip to 74% (from 82% in FY23) as weight-loss shipping cadence and international mix weigh on the mix. Management is betting that owned manufacturing eventually pulls it back.

The story on this chart is the orange line. Gross margin has been drifting down for two years. What flipped the economics was marketing efficiency as the brand scaled and the subscriber base got old enough to contribute free revenue.

The Playing Field

Hims & Hers has no real peer at scale. The "DTC telehealth" category is an optical illusion — put it next to the only company with comparable revenue (Teladoc), and it's a completely different business, and put it next to the businesses with the same model (LifeMD), and it's ten to twelve times their size.

Three observations the peer set forces on you:

• No one else is growing and making money. Teladoc is a declining B2B/payer business; American Well is still burning 40 cents for every revenue dollar after a decade; WW is the post-bankruptcy shell of a category that GLP-1s broke. HIMS is the only company in this set that is positive on both axes.
• The closest analog is LifeMD, at 1/12th the size. LFMD is the honest comp — DTC Rx subscription, similar ARPU, better gross margin, slower growth, sub-scale marketing. It shows what HIMS would look like without the brand and the Super Bowl budget.
• "Telehealth market share" is the wrong frame. Management cites being "roughly twice the size of the next largest U.S. telehealth provider" on a transaction-panel basis (Bloomberg Second Measure, sexual health / derm / mental health / weight loss). That is a DTC subscription-pharmacy slice, not the broader telehealth market Teladoc competes in. Treat the TAM claims accordingly.

The more interesting competitor is not in this table: it's Amazon Pharmacy + One Medical and the branded GLP-1 manufacturers (Novo, Lilly) direct-to-consumer. Amazon's November 2024 push into telehealth knocked the stock; its April 2026 weight-loss program did the same. This is where the threat lives, not in the publicly traded "telehealth" peer group.

Is This Business Cyclical?

Not in the classical macro sense — subscription health/wellness is shallowly discretionary and GDP-insensitive. The real cycle is regulatory, and it runs on an unpredictable clock.

The stock has oscillated 20–50% in single weeks on these events. A few things to understand about the mechanism:

Where the cycle actually hits: not demand (subscribers still want cheaper Ozempic); not pricing (compounded is already the cheap version); but legal right to exist. A single FDA list update can take a $200M/year product category off the platform in a quarter. Weight-loss offerings carry shorter shipping cadences and heavier fulfillment costs, which is why FY25 gross margin fell 500 bps — so the category is also the lowest-margin one to defend.

The comforting counter-fact: management has been explicit that the majority of FY25 revenue came from non-GLP-1 offerings, and Hers (weight-loss + derm) still grew >100% despite the February 2026 FDA statement naming the company. Each of Hims and Hers has multiple $100M+ specialties — sexual health, hair loss, and dermatology predate GLP-1s and keep compounding. Pull GLP-1 out of the model and you still have a profitable, growing DTC subscription pharmacy; you just don't have a 60% top-line growth rate.

Macro exposure is real but second-order. Consumer discretionary cuts would hit CAC efficiency (ad auction inflation) and retention at the margin. Trade and tariff actions on API sourcing would hit COGS. Neither of these is in the stock today.

The Metrics That Actually Matter

Forget the traditional retail-pharma ratios. There are really five numbers that decide whether this company is creating value.

What I'd Tell a Young Analyst

Stop thinking of this as a telehealth company. It is a DTC subscription pharmacy with a Super Bowl ad budget. Model it like Dollar Shave Club with compounded prescriptions, not like Teladoc. Every analytical mistake on this name comes from using the wrong comp set.

Separate GLP-1 from the rest of the business in your model. Build two lines: a base case (everything but compounded semaglutide/tirzepatide) and an optional GLP-1 contribution. The base case is profitable, 30–40% growth, 70%+ personalized mix, durable. The GLP-1 line is a binary regulatory bet worth modeling as an option. Most sell-side decks blend these and get surprised both directions.

Three things would change the thesis. First, marketing payback extending past 12 months (historically stable at 6–7 — if that breaks, the whole model is cosmetic). Second, FCF failing to recover in 2026 as capex rolls off — management has been investing $300M in facilities, and if that doesn't earn its return by 2027 the owned-pharmacy story is bluster. Third, a definitive FDA move on GLP-1 compounding that doesn't just restrict it but also drags non-GLP-1 compounding into its ambit (testosterone, minoxidil personalization) — this is the tail risk nobody is modeling.

What the market is underestimating: Eucalyptus (up to $1.15B, closes mid-2026) makes HIMS a genuine global DTC health platform with $450M+ of international run-rate revenue and access to Australia, Germany, UK, Japan, Canada in one stroke. That changes the TAM conversation and gives management a runway to hit the 2030 target of $6.5B revenue / $1.3B EBITDA even if US GLP-1 evaporates. Almost nobody in the US telehealth conversation is pricing Eucalyptus.

What the market is overestimating: the durability of the 2025 gross-margin story. Gross margin fell 500 bps in a year and will keep drifting as weight-loss, international, and new specialties mix in. Management will tell you scale fixes it; history says mix wins. If you build your model with stable 74% gross margin, you are almost certainly wrong.

Watch Q1 FY26 for two tells: the pace at which compounded GLP-1 revenue shrinks post-FDA statement, and whether the payback period stays inside 8 months. Those two numbers dictate whether 2026 guidance of $2.7–2.9B revenue / $300–375M Adj EBITDA is conservative or brave.

The Numbers

Hims & Hers is a direct-to-consumer telehealth subscription business that has compounded revenue at roughly 63% per year for three years while pivoting from GAAP losses to mid-single-digit net margins. But the FY2025 print hides a sharp intra-year slowdown: quarterly YoY growth decelerated from +111% in Q1 to +28% in Q4, gross margin fell from 82% to 74%, and the balance sheet swung from essentially debt-free to carrying $973M of convertible notes. At an EV/EBITDA of roughly 46x on TTM numbers, the single metric most likely to rerate or derate this stock is gross-margin stability over the next two quarters — everything else (growth, unit economics, valuation) keys off whether the compounded-GLP-1 drag is structural or transitional.

Snapshot

Shares outstanding of 219.6M against today's $29.01 close gives a ~$6.4B market cap; adding the $973M of convertible debt and netting $929M of cash and investments puts enterprise value near $6.4B, about 2.7× TTM revenue and 46× TTM EBITDA of roughly $178M.

Is this a healthy, well-run business?

A standard quality scorecard anchors on the three things that actually matter at this stage: does it earn a return on capital, can it pay its bills, and are reported earnings turning into cash.

HIMS generates a 23.7% ROE and 13.9% ROIC on a newly enlarged capital base — both high for a consumer services business. Cash conversion is the standout: operating cash flow of $300M came in at 2.3× GAAP net income, meaning the reported 5.5% net margin understates the true cash-generation of the model. The watch-list item is leverage: debt-to-equity jumped from 0.02 in FY2024 to 1.80 in FY2025 after the $970M convertible raise.

Revenue & earnings power

Revenue has gone from $872M → $1.48B → $2.35B in three years — a 2.7× cumulative lift. Operating income flipped from a $29M loss to a $106M profit without revenue mix appearing particularly lucrative; the operating-leverage story is real. But the margin chart flags the other half: gross margin gave back 800bps as FY25 progressed, and operating margin barely inched up despite revenue nearly doubling.

Quarterly direction — the deceleration question

Revenue dollars are still climbing, but the growth-rate chart is unambiguous: YoY growth went from 111% in Q1 FY25 to 28% in Q4 FY25 — a four-quarter deceleration. Q2 FY25 revenue actually dipped sequentially versus Q1, the first down quarter since IPO, reflecting the compounded-semaglutide unwind.

Cash generation — are the earnings real?

Operating cash flow ran $300M in FY25 against $128M of GAAP net income — a 234% conversion ratio. The main reason is stock-based compensation: $135M of SBC is added back as non-cash, so "cash earnings" are inflated by paying employees with equity that dilutes shareholders elsewhere. SBC as a share of revenue is declining (7.6% → 5.8%), which is the right direction, but in dollar terms it doubled in two years. Adjust net income for SBC and the real economic margin is closer to break-even, not the reported 5.5%.

Capital allocation & balance sheet shift

The right-hand chart tells the FY2025 story cleanly: HIMS raised $970M in convertible notes, spent $637M buying investments, $145M on a business acquisition (primarily the Wholesome / compounding infrastructure bolt-on), and $72M buying back stock — all funded by the debt raise plus $300M of operating cash. Net debt swung from -$290M (net cash) in FY24 to +$44M in FY25. The company now carries more leverage than it has at any point since IPO, but still holds $929M of liquidity to deploy.

Valuation — where it trades vs its own history

The stock peaked at $72.98 intraday on Feb 19, 2025 and has since retraced roughly 60% to $29. The fall was not a single event — it unwound over 14 months as three things happened in sequence: the FDA resolved the GLP-1 shortage (cutting off compounded semaglutide sales), gross margin compressed, and Q4 growth decelerated to 28%. At 2.7× sales today versus 3.6× at the FY2024 close, valuation has de-rated meaningfully but is still above the 2.1× multiple of FY2023 (when the business was unprofitable).

Peer comparison

Of the four public telehealth / direct-to-consumer health peers, HIMS is the only one profitable on a GAAP basis and the only one with a positive gross margin comparable to a software business. TDOC has similar revenue scale but is burning $200M a year; LFMD is profitable but a tenth the size; AMWL and WW are structurally challenged. The premium multiple HIMS commands versus peers is justified by unit economics; the question is what's the right multiple for a business whose growth rate just fell from 100%-plus to sub-30%.

Fair value scenario

The wide spread between bear ($17) and bull ($44) reflects the underlying binary: if compounded-GLP-1 revenue is a permanent drag, FY26 growth compresses below 20% and the multiple goes with it. If the core sexual-wellness / hair / mental-health verticals keep compounding and international launches land (mgmt called out a $1B+ opportunity on the Q3 call), the current multiple is defensible.

What the numbers say

The numbers confirm that HIMS is a genuinely profitable telehealth business with industry-best gross margins, a $2.3B revenue base, and a cash-generative model that converts more than 100% of GAAP earnings into operating cash flow. They contradict the bullish narrative that growth is durable at the pace of 2024 — the quarterly trajectory is a clean four-quarter deceleration and the margin compression is not yet priced as structural. What to watch in Q1 and Q2 FY2026: gross margin stability (a print above 72% would relieve pressure; below 70% would confirm the bear case), net-add trajectory ex-GLP-1, and whether the $929M on the balance sheet is deployed into return-generating acquisitions or sits as negative-carry treasuries against 0.25% convertible coupons.

The People Running This Company

Governance grade: C-. Andrew Dudum owns roughly 7% of the economics but commands 88% of the votes through super-voting Class V shares. Every other governance fact on this page — the deep, qualified board, the stock-ownership guidelines, the clawback policy, the anti-pledging rules — lives downstream of that one number. Add $43M of insider selling in 13 months, zero insider buying, $4.1M of related-party payments to the COO's spouse's company, and a $24.6M CEO pay package at a company that lost money on a GAAP basis in 2024, and the picture is "high-conviction founder play, buy the chairman not the business."

1. The People Running This Company

Dudum is the whole story. He founded Hims inside his own venture studio (Atomic Labs) at 27, took it public via SPAC at 31, and now runs a $6B-revenue company at 37 with no check on his authority. The three lieutenants who actually build the business — Okupe (finance), Chi (growth), Boughton (legal) — are capable but have been at the company less than five years each. The COO seat has turned over twice in 2025 alone (Baird out May 2025, Kabbani out November 2025, Chi promoted in), which is unusual turbulence for a company of this size at a moment of peak regulatory scrutiny.

2. What They Get Paid

Pay is aggressive but not outrageous by telehealth-peer standards. The composition is what matters: 92% of Dudum's package is equity, tied in large part to stock-price performance hurdles ($38.31 vesting trigger was hit in Feb 2025). The 200% bonus payout for 2024 is defensible — revenue came in at 112% of target and adjusted EBITDA at 153% of target. The $180K "home security reimbursement" inside "All Other Compensation" is the one line that sticks out as a personal perk; most peer CEOs at this size don't get one.

What drags the optics: Dudum's economic package is 43x the median employee, he didn't take an option grant in 2024 (only RSUs/PRSUs), and the pay committee is chaired by Andrea Perez, a first-time public-company compensation chair whose independence lives within a board Dudum controls via a vote he can never lose.

3. Are They Aligned?

Ownership and control

One share of Class V equals 175 votes of Class A. Dudum holds every Class V share (via his trusts). The practical result is that BlackRock and Vanguard — who together own 19% of the economics — control roughly 2.5% of the votes. Every share outside the founder's trusts is voting in an advisory capacity. This is among the most extreme voting-rights imbalances in the entire US mid-cap universe.

A dormant but worth-noting provision: if Class V ever converts to Class A, the board automatically becomes classified into three staggered classes. In other words, if Dudum ever loses voting control he has pre-armed the company with a takeover defense.

Insider buying vs. selling

Not a single insider bought a share in the open market during the 13 months on record. Over the same window insiders sold $43.2M, with the heaviest activity in September–October 2025 when the stock printed all-time highs above $60. The CFO sold $11.6M in two September days alone, mostly at $55-60; the same insider is still selling now at $25-30. Dudum sold $15.3M in two concentrated windows — 2025-09-16/17 and 2025-10-16 — entirely at $50-63, and has not sold since.

The pattern is what's disqualifying. Heavy, coordinated selling at local highs, followed by silence when the stock halved (after the Novo Nordisk breakup in June 2025 and the compounded-GLP-1 regulatory noise), then resumption of mid-sized CFO sales in April 2026. The data does not tag 10b5-1 plans explicitly, but the metronomic tranche pattern of Okupe's sales is consistent with a plan. Either way: when management was closest to a regulatory inflection, they took money off the table.

Dilution and equity cost

Equity awards to named officers in 2024 alone totaled $47.3M of stock grants on top of $24.6M of cash-and-perks. With SBC running at a multi-hundred-million-dollar annual rate and net income only modestly positive, essentially all GAAP profit is being returned to insiders via equity. Dilution is continuing: Dudum received 794,002 shares on 2026-02-23 and 413,844 more on 2026-03-11 as annual grants, with a Feb 2025 milestone already having vested another 1.6M performance options plus 162K RSUs.

Related-party transactions

The Vouched arrangement is the only material one, and it is sizable — $4.1M to a vendor controlled by the former COO's spouse is not a trivial sum. The company claims the contract is on market terms; the shareholder has to take that on faith because no comp comparison is disclosed. Atomic Labs is not listed as a related party, but Dudum's continued co-founder role there is a governance hair: any future commercial dealing between Hims and an Atomic portfolio company would be an obvious flag.

Skin-in-the-game score

• Control vs. capital (−): 88% of the votes against 7% of the economics is the textbook definition of misaligned voting rights.
• Buying behavior (−): Zero open-market purchases by any insider in the past two years.
• Selling behavior (−): $43M of selling concentrated at the all-time high.
• Ownership stock (+): Dudum does hold ~$500M+ of Hims stock outright; he is wealthy on paper through the same shares public holders own, so the downside scenario (stock going to $5) hurts him too.
• Ownership guidelines (+): 5x salary for CEO, 2.5x for execs, 5x cash retainer for directors — adopted July 2024, compliance achieved.
• Anti-hedging / anti-pledging (+): Explicitly prohibited in the insider-trading policy.

The founder is wealthy through the stock, which is a real alignment. But control without corresponding capital and a selling pattern that looks like peak-timing outweigh the stock-ownership box-checking.

4. Board Quality

On paper this is a strong board. David Wells (Netflix CFO for 8 years, now chairs Wise and sits on Trade Desk's audit committee) is an unusually heavyweight lead independent director for a $6B company. Kåre Schultz ran Teva Pharmaceutical — directly relevant to the branded-versus-compounded GLP-1 fight. Deb Autor spent 12 years at the FDA, including as Deputy Commissioner for Global Regulatory Operations — she is exactly the hire you'd make before a regulatory dust-up, although she also took a paid consulting arrangement that blurs her independence. Chris Payne ran DoorDash as COO. Toby Cosgrove ran Cleveland Clinic. This is a top-quartile slate of public-company expertise.

The problem is not expertise. It is power. When one person controls 88% of the vote, every independent director serves at the pleasure of that one person. Say-on-pay is advisory. Board elections are annual but uncontested. There is no conceivable vote that can go against Dudum. An entire board's worth of Netflix CFOs and FDA deputies cannot make the shareholder votes count.

5. The Verdict

What would make it a B: Dudum sunsets Class V voting after a defined period (a path Meta and Google have refused but Snap and some others have offered). Or the CFO completes his 10b5-1 program and insiders resume buying after the next regulatory shoe drops. Or the Vouched arrangement gets competitively re-bid and disclosed. Or the board formally separates the CEO and Chair.

What would take it to D: An SEC or FDA enforcement action tied to compounded GLP-1 marketing where the board cannot demonstrate it pushed back in real time. A material new related-party disclosure involving Atomic Labs. A repeat episode of fast, pre-inflection insider selling without a disclosed 10b5-1 trail.

The strongest positives: A genuinely qualified board (Netflix CFO, Teva CEO, FDA veteran, Cleveland Clinic CEO), robust policy infrastructure (clawback, anti-pledging, ownership guidelines), and a CEO-founder with meaningful personal wealth in the stock. Pay is high but performance-linked; the 2024 payout was earned by beating revenue and EBITDA targets.

The real concerns: Voting control without proportional economic ownership, $43M of insider selling concentrated at peak prices with zero buying, a $4.1M related-party vendor tied to a former executive, CEO-Chair combined and also chairing Nominating & Governance, and a COO seat that turned over twice in a single year during the company's most regulatory-sensitive chapter.

The one thing that would flip the grade: Dudum voluntarily agrees to sunset Class V super-voting rights at a fixed future date. Until then, this is a company where shareholders are along for the founder's ride — which is fine when the founder is executing, and extremely not fine when he isn't.

The Full Story

From 2021 to 2024, Hims told an unusually consistent story: a multi-specialty telehealth subscription business scaling toward profitability. Q2 2024 broke the pattern when the compounded GLP-1 launch reshaped the growth algorithm, the risk profile, and ultimately the company's identity. Management has delivered every quarterly guide through 2025 and beat two sets of "long-term" targets on an accelerated timeline — but the Novo Nordisk partnership collapse, FDA naming, DOJ referral, and Q4 2025 subscriber deceleration mark the first genuine credibility stress in the company's public-market history. The current $6.5B 2030 revenue target is now the central stake.

1. The Narrative Arc

The story has rewritten itself roughly every four quarters — each time expanding the TAM rather than admitting to an earlier overpromise. The result is an arc that looks confident on the surface but reveals quietly retired promises at each inflection.

2. What Management Emphasized — and Then Stopped Emphasizing

Topic emphasis has rotated sharply. Themes that dominated 2023 letters ("four strategic pillars," "access") quietly disappeared by 2024. "GLP-1 / compounded weight loss" went from dominant in 2024 to retroactively demoted by Q4 2025 ("majority of 2025 revenue came from non-GLP-1 offerings"). Intensity scored 0 (absent) to 5 (headline theme).

Three patterns stand out:

• "Four strategic pillars" (trusted brand / technology / product innovation / clinical excellence) — the central 2023 framing — was wiped from the letters by Q1 2024 without acknowledgment.
• GLP-1 went from one-phrase mention (Q2 2023) to headline theme (Q2 2024 through Q1 2025) to retroactive demotion (Q4 2025) when the Novo Nordisk partnership collapsed.
• International + Labs + Longevity/Peptides are the new dominant themes — all three were absent before Q4 2024. The story is being recomposed faster than the underlying business can prove it.

3. Risk Evolution

The 10-K risk factors track the business transformation with a roughly 4-quarter lag. Pandemic and "early-stage business" risk language retired as the company matured. All of the most severe current risks (GLP-1, compounding, FDA/FTC scrutiny, international regulation, $1B convertible leverage, Eucalyptus integration) are new since FY2024.

• Dropped quietly: "limited operating history" (bullet removed from FY2024 summary); pandemic tailwind reversal (removed FY2024); Truepill partner-pharmacy reliance (Truepill dropped from filings from FY2023 onward as internal fulfillment scaled).
• New and severe in FY2024: GLP-1 compounded drug risk; 503B outsourcing facility regulation; perception of safety/efficacy of compounded drugs; AI-related regulatory and reputational exposure.
• New and severe in FY2025: FDA warning letters (Sep 2025, explicitly naming Hims); HHS referral to DOJ (Feb 2026); Novo Nordisk patent infringement lawsuit; Eucalyptus acquisition integration risk; $1.0B 2030 convertible notes debt service; LDT/clinical lab regulation (post-Trybe); multi-jurisdictional foreign regulation (Canada PHIPA, UK MHRA/GPhC, EU EMA); tariff/trade actions. The risk profile in FY2025 is unrecognizable from FY2021.

4. How They Handled Bad News

The pattern is consistent: quick reframes, light on direct admission. Major negative events — the FDA shortage resolution, the Novo Nordisk termination, the sexual-health slowdown, Q4 2025 subscriber deceleration — were each reframed as strategic evolution rather than confronted as setbacks.

5. Guidance Track Record

Hims met or beat every quarterly guide from FY2023 through FY2025. But the bigger story is in the long-dated promises: each one was either pulled forward aggressively (a positive signal) or quietly retired (a negative one).

Credibility observations:

• FY2023 and FY2024 were massive beats — the original 2025 "$1.2B rev / $100M EBITDA" target was delivered a full year early and blown past by 48% on EBITDA.
• FY2025 was an "on-target" year — first time a major guide landed at midpoint rather than beating, signaling the growth algorithm stabilizing.
• FY2026 is the first guide with Adj. EBITDA midpoint below the prior year's actual ($337M vs $318M FY25). Implied revenue CAGR to hit the 2030 $6.5B target from FY25 is ~29% — achievable, but the first-year step is 18% at midpoint.
• The $725M 2025 weight-loss promise is the cleanest example of a quiet retirement — never reported against, retroactively diluted by "the majority of 2025 revenue came from non-GLP-1 offerings."

6. What the Story Is Now

The current story is "largest consumer-first personalized health platform, globalizing via acquisition, with GLP-1 as a contributing vertical." That is a meaningfully different pitch than "the telehealth subscription compounder with $725M of weight loss revenue" that prevailed through Q1 2025.

What has been de-risked:

• Profitability is real — three straight years of GAAP operating profit, $2.35B revenue, 14% Adj. EBITDA margin, though inflated by a one-time $54M tax benefit in FY2024.
• Personalized offerings are now >70% of US revenue and drive higher monthly revenue per subscriber ($81 in FY25 vs $51 in FY21).
• Compounded GLP-1 regulatory overhang is partially resolved via the March 2026 Novo Nordisk agreement (distributing branded Wegovy/Ozempic; Novo dropped its lawsuit).

What still looks stretched:

• The 2030 $6.5B / $1.3B target requires revenue CAGR of ~29% from FY25 — while FY26 initial guide implies only 15–23% and subscriber growth decelerated to +13% YoY in Q4 25.
• Margin math — branded Wegovy distribution carries structurally lower margin than compounded; FY26 Adj. EBITDA midpoint is already below FY25 actual; the "20% long-term margin" promise is not yet earned.
• International is the single largest remaining TAM expansion claim (>$1B in 3 years). ZAVA, Medici, Eucalyptus, YourBio — four acquisitions in 12 months — are not yet integrated and have consumed most of the FCF (collapsed from $198M to $57M in a single year). Eucalyptus integration is flagged as a brand-new risk section in the FY2025 10-K.
• Peptides / longevity is a narrative-heavy, evidence-light vertical dependent on regulatory loosening (RFK Jr. push). It is priced into the story but not yet into the P&L.

What to believe vs. discount:

What's Next

Next earnings: May 11, 2026 (after close). Consensus calls for Q1 FY26 revenue of ~$621M (+6% YoY) and EPS of ~$0.06 — roughly a 70% YoY decline from Q1 FY25's $0.20, the first full quarter absorbing the branded Wegovy pivot. That single print is the pivot point: it is the first clean window into whether the margin compression the bull calls "stabilizing" and the bear calls "collapsing" actually shows up in the numbers.

The Street is already positioned below spot — mean 12-month target $24 despite a 37% one-month rally — and BofA (the most recent update, April 16) raised only to $25 with a neutral rating, citing ~50% YoY EBITDA compression from the Wegovy shift. What the market watches most closely on May 11 is not revenue (estimates are tight around $621M) but the gross margin and Adj EBITDA walk that tells you how much of the 800bps FY25 gross-margin drop is one-time vs structural.

For / Against / My View

Bull and Bear have already written the two sides of this name in full rigor. What follows is selection, not re-drafting — the sharpest three points from each, the places they actually disagree on the same number, and where the weight of evidence lands.

For

Primary catalyst: Q2 FY26 print showing gross margin stabilizing at 72%+ while Eucalyptus closes and begins contributing to FY27 run-rate — supports a re-rating to 3.5x forward revenue / 30x FY27 EBITDA. Disconfirming signal: paid-marketing payback extends beyond 9 months (historically 6–7 months for four years).

Against

Primary trigger: Q1 or Q2 FY26 gross margin prints under 72% and/or Adj EBITDA margin under 11% — confirming the Wegovy pivot is margin-dilutive and forcing a cut to the FY26 midpoint guide. Covering signal: Q2 FY26 reclaims 74%+ gross margin with Adj EBITDA run-rate above $350M and subscriber growth re-accelerates past 20%.

The Tensions

1. Gross margin — residual shock or the leading edge of permanent compression?

Bull reads the FY25 74% gross margin as the trough of a one-year compounded-semaglutide mix shift with personalized SKUs (70% of US revenue, 85%+ contribution) preserving structural pricing power. Bear reads the exact same 74% as the leading edge of permanent compression — 800bps already gone before branded Wegovy hits the P&L, and Wegovy at $599 is a distribution fee, not a manufactured margin. Both cite FY25 gross margin of 74%, down from 82%. This resolves on the Q1 FY26 print on May 11 and, more definitively, Q2 FY26 in August: a print at 72%+ supports the bull; under 72% confirms the bear.

2. Cash — is $300M OCF or $57M FCF the right number?

Bull cites FY25 operating cash flow of $300M (2.3x GAAP net income) as proof HIMS has become a cash machine that can self-fund Eucalyptus out of the $929M on the balance sheet. Bear cites FY25 free cash flow of $57M (down 71% from $198M) on $243M of capex as proof the cash model is already broken — EBITDA-to-FCF conversion at 18%. Both cite the same FY25 cash statement. This resolves on the FY26 capex disclosure (first revealed on the May 11 print) and the FY26 FCF trajectory: capex normalizing toward $75–100M and FCF recovering above $150M vindicates the bull; capex staying above $200M while FCF remains under $75M confirms the bear.

3. CFO Okupe's April 6–22 sales — legacy 10b5-1 plan or live monetization?

Bull reads the ~78,500-share tranche at $20–30 as metronomic 10b5-1 execution of a plan filed when the stock sat at $50–60 — pre-dated, uninformed, not a new signal. Bear reads the same tranche as the latest chapter of an unbroken 13-month pattern ($43.2M out, zero buys), with the CFO selling into a 37% one-month rebound at prices 60% below his original sell zone. Both cite the same April 6–22 CFO Form 4s. This resolves on whether Okupe files a new 10b5-1 after the May 11 print (and at what price), and whether Dudum opens any open-market purchases within the next trading window — a new plan at current prices supports the bull; continued Okupe selling with silence from Dudum confirms the bear.

My View

Close call, but the slight edge goes to the cautious side. The For case rests on forward assertions — Eucalyptus scaling, a peptide revenue stream conditional on the July PCAC, non-GLP-1 compounding at 30%+ in isolation — while the Against case rests on numbers that are already in the print: a FY26 guide where EBITDA grows slower than revenue, FCF at 18% of EBITDA, 800bps of gross-margin compression before branded Wegovy hits, and 13 months of one-directional insider activity. Tension #1 tips it — the Q1 FY26 gross-margin print on May 11 is the first unambiguous piece of evidence either side has been arguing about, and it lands before any of the bull's positive catalysts (Eucalyptus close, July PCAC, Q2 re-acceleration). I'd wait for that number. A 72%+ gross margin with Adj EBITDA on a $350M+ run-rate — the bear's own covering signal — flips this view and reframes the Wegovy transition as margin-neutral rather than margin-destructive.

Web Research — What the Internet Knows

The Bottom Line from the Web

The web tells a very different story than the financials alone. HIMS spent the past 15 months riding a compounded GLP-1 boom that pushed revenue from $1.48B (2024) toward $2.3B+ (2025), but the last 90 days have been a full-scale regime change: a February 2026 FDA crackdown forced it to withdraw its $49 compounded semaglutide pill days after launch, the SEC opened a disclosure investigation, Novo Nordisk sued for patent infringement — and then in a startling reversal, HIMS transformed the lawsuit into a distribution partnership, signed a $1.15B deal for Australia's Eucalyptus, and began selling branded Wegovy/Ozempic at $599/month. The stock sits ~60% below its July 2025 high with analyst price targets now clustered at $21–$23, yet rallied 49% in the back half of April on a peptide-facility acquisition and a favorable Washington policy turn.

What Matters Most

9. CEO Andrew Dudum's 2024 compensation was $24.6M — 97.7% equity-linked, 2.3% cash. Base $572,917, bonus $1.14M, stock awards $22.7M, other $183K. Dudum founded the company in 2017 via Atomic venture studio and remains both CEO and Chairman. Source: salary.com, simplywall.st.

10. New COO Mike Chi (started Nov 2, 2025). Succeeded Nader Kabbani; now leads the international scaling playbook (ZAVA integration UK/Europe, Eucalyptus integration APAC). This is the most consequential org change in 18 months — HIMS is building an M&A integration competency on the fly. Source: gurufocus.com, insidermonkey.com.

Recent News Timeline

The timeline shows a bimodal pattern: a cluster of legal/regulatory shocks in February 2026 that cut the stock in half, followed by an April rebound driven by M&A, policy, and partnership resolution. In parallel, insider selling has been accelerating into the April rally — not out of the February trough.

What the Specialists Asked

Insider Spotlight

Andrew Dudum — CEO / Chairman / Founder. 9.6-year tenure. 2024 total compensation $24.6M with 97.7% equity-linked. Co-founded via Jack Abraham's Atomic venture studio. Wikipedia confirms continuous CEO tenure since 2016. No Form 4 sells surfaced in this search cycle — CFO Okupe and the CLO dominate the April transaction tape.

Yemi Okupe — CFO. Six documented sales in five weeks (March 18 through April 22, 2026) covering roughly 108,000 shares, all under a pre-filed Rule 10b5-1 plan. Post-Apr 20 holdings: 262,954 shares (~$7.88M at $29.96). Wall Street consensus per FinancialContent views Okupe "favorably for disciplined capital allocation" — but the trading tape reads as diligent monetization of the rebound.

Mike Chi — COO (since Nov 2, 2025). Succeeded Nader Kabbani. Now the operating lead on international integration (ZAVA + Eucalyptus). Short tenure — under six months — at the most critical operational moment in the company's history.

Deb Autor — Director (joined Nov 2024). Former FDA Deputy Commissioner. Board recruitment of former FDA leadership was prescient given the February 2026 FDA action; the signal value of this appointment has since become obvious.

Industry Context

Global telehealth is on a ~24% CAGR path to approximately $680B by 2030 per Business Research Company; Fortune Business Insights pegs a similar trajectory. The US sub-segment grew at a more modest 4.7% CAGR 2021–2026 per IBISWorld — structural growth is real but less spectacular than global headline numbers imply, and most of it is virtual-consultation volume, not DTC pharmacy.

Three structural shifts in a three-week window (late March through mid-April 2026) redefined HIMS's competitive set:

1. FDA approves Eli Lilly's oral GLP-1 pill (Apr 1, 2026). Opens the branded oral weight-loss market — precisely the product category HIMS tried to enter via compounding.
2. Novo Nordisk launches Wegovy subscriptions (Mar 31, 2026). Direct-to-consumer subscription attack on DTC telehealth.
3. Amazon launches GLP-1 weight-loss program (Apr 21, 2026). Pharmacy + logistics scale against a pure-DTC telehealth model.

The telehealth M&A environment is active. MergersAndAcquisitions.net (Jan 2026) notes strong deal flow in telehealth services M&A; HIMS's Eucalyptus transaction fits this consolidation narrative. The competing thesis — that regulatory drag and Big Pharma vertical integration will compress telehealth margins — is visible in the sell-side price-target spread.